Lyell Immunopharma Inc.

06/26/2024 | Press release | Distributed by Public on 06/26/2024 06:42

Initial Clinical and Translational Data from Phase 1 Trial of LYL797, an Enhanced ROR1 targeted CAR T Cell Product Candidate